Cor Vasa 2007, 49(10):K286

Stránka k zamyšlení: Ananda

Published: October 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Stránka k zamyšlení: Ananda. Cor Vasa. 2007;49(10):K286.
Download citation

References

  1. Reaven GM. Non-insulin-dependent diabetes mellitus, abnormal lipoprotein metabolism, and atherosclerosis. Metabolism 1987; 36 (Suppl 1):1-8. Go to original source... Go to PubMed...
  2. Šochman J. Nemoc tučných jater a statiny - kterému oboru patří tento problém? Čas Lék čes 2006;145:443-6.
  3. Hradec J. Endokanabinoidní systém - nový léčebný cíl u multirizikových nemocných. Remedia 2005;15:163-8.
  4. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. RIO-North America Study Group. Effect of rimonabant, a cannabionoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-75. Go to original source... Go to PubMed...
  5. Despres JP, Golay A, Sjostrom L. Rimonabant in Obesity-Lipids Study group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New Engl J Med 2005;353:2121-34. Go to original source... Go to PubMed...




Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.